Transforming precision medicine: The potential of the clinical artificial intelligent single-cell framework

Abstract

	•Integration of AI with Single-Cell Informatics for Precision Medicine: The caiSC system combines artificial intelligence and single-cell data to improve diagnostics, treatment predictions, and personalized medical decision-making.
	•Challenges in Data Coverage and Model Robustness: caiSC currently faces limitations due to incomplete data across cell types, diseases, and organs, as well as challenges in data quality and high computational demands, which affect model accuracy and clinical applicability.
	•Future Potential and Regulatory Needs: The caiSC framework’s development could lead to innovations such as digital cell twins, enabling personalized simulations of cellular responses for better treatment planning, though regulatory certification is essential for safe clinical use.

Keywords

Artificial Intelligence / Digital Cell Twins / Precision Medicine / Predictive Diagnostics / Regulatory Approval / Single-Cell Informatics

References

[1] Wang X, Powell CA, Ma Q, Fan J. Clinical and translational mode of single-cell measurements: an artificial intelligent single-cell. Clin Transl Med. 2024;14(9):e1818.

[2] Quazi S. Artificial intelligence and machine learning in precision and genomic medicine. Med Oncol. 2022;39(8):120.

[3] Rozenblatt-Rosen O, Stubbington MJT, Regev A, Teichmann SA. The Human Cell Atlas: from vision to reality. Nature. 2017;550(7677):451-453.

[4] Carini C, Seyhan AA. Tribulations and future opportunities for artificial intelligence in precision medicine. J Transl Med. 2024;22(1):411.

[5] Baumgartner C. The world’s first digital cell twin in cancer electrophysiology: a digital revolution in cancer research? J Exp Clin Cancer Res. 2022;41(1):298.

[6] Bordukova M, Makarov N, Rodriguez-Esteban R, Schmich F, Menden MP. Generative artificial intelligence empowers digital twins in drug discovery and clinical trials. Expert Opin Drug Discov. 2024;19(1):33-42.

[7] U.S. Food & Drug Administration (FDA). Proposed regulatory framework for modifications to artificial intelligence/machine learning (AI/ML)-based software as a medical device (SaMD)-discussion paper and request for feedback. 2019. Available from: https://www.regulations.gov/document/FDA-2019-N-1185-0001

[8] U.S. Food & Drug Administration (FDA). Clinical decision support software guidance for industry and Food and Drug Administration staff. 2022. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-decision-support-software

[9] International Medical Device Regulatory Forum (IMDRF)/Artificial Intelligence Medical Devices (AIMD) Working Group. Machine learning-enabled medical devices: key terms and definitions. 2022. Available from: https://www.imdrf.org/sites/default/files/2022-05/IMDRF%20AIMD%20WG%20Final%20Document%20N67.pdf

[10] Subramanian M, Wojtusciszyn A, Favre L, et al. Precision medicine in the era of artificial intelligence: implications in chronic disease management. J Transl Med. 2020;18(1):472.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.